Ruxolitinib (S enantiomer)

Ruxolitinib (S enantiomer) (S-Ruxolitinib) is the S-enantiomer of Ruxolitinib (HY-50856) . Ruxolitinib (S enantiomer) is an orally active, potent JAK inhibitor[1][2].

Product Specifications

CAS Number

[941685-37-6]

Product Name Alternative

S-Ruxolitinib; S-INCB18424

UNSPSC

12352005

Target

JAK

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ruxolitinib-s-enantiomer.html

Concentration

10mM

Purity

99.94

Solubility

1M HCl : 50 mg/mL (ultrasonic; adjust pH to 1 with HCl) |DMSO : ≥ 100 mg/mL

Smiles

N#CC[C@@H](C1CCCC1)N2N=CC(C3=NC=NC4=C3C=CN4)=C2

Molecular Formula

C17H18N6

Molecular Weight

306.37

References & Citations

[1]Hye Kyung Lee, et al. JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells. Commun Biol. 2021 Jun 2;4 (1) :654.|[2]Lorena Arranz, et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014 Aug 7;512 (7512) :78-81.